Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.…
Learn Why The Bull Case For Viking Therapeutics Stock Could Change Following Obesity Drug Trial Progress
Viking Therapeutics (NASDAQ: VKTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 74 employees.
The shares were at 24.77 USD on 20 November 2026, down 33.5% over 52 weeks. Its 52-week range is 23.82 USD to 43.15 USD: the price is 42.6% below the high and 4.0% above the low.
Its market capitalisation is 3.16B USD.
Viking Therapeutics reports return on equity of -56.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 705.12M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 95.32 USD is 284.8% above the current price. The next earnings report is expected on 10 February 2027.